14:51:11 EDT Thu 28 Mar 2024
Enter Symbol
or Name
USA
CA



Stellar Biotechnologies Inc
Symbol KLH
Shares Issued 75,865,031
Close 2013-12-31 C$ 1.88
Market Cap C$ 142,626,258
Recent Sedar Documents

Stellar Biotechnologies releases 2013 results, no details

2014-01-02 09:11 ET - News Release

Mr. Frank Oakes reports

STELLAR BIOTECHNOLOGIES ISSUES YEAR-END RESULTS AND HIGHLIGHTS FROM 2013

Stellar Biotechnologies Inc. has filed its annual report for the fiscal year ended Aug. 31, 2013, and financial results and operational highlights for 2013.

Selected highlights from 2013

New corporate partnership

Stellar executed a collaboration agreement with Amaran Biotechnology Inc. in December, 2013, to develop and evaluate methods for the manufacture of OBI-822 active immunotherapy using Stellar's GMP grade KLH. OBI-822 is the lead immunotherapy product of OBI Pharma Inc., manufactured by Amaran and currently in phase II/III clinical trials in the United States, Taiwan, South Korea, India and Hong Kong, for the treatment of metastatic breast cancer. The collaboration involves an important, multinational clinical project with long-term product development and commercial potential.

Strengthened balance sheet

In September, 2013, Stellar raised $12-million (U.S.) in gross proceeds in a private financing that included a $5-million (U.S.) investment by Amaran Biotechnology Inc., a privately held Taiwan biopharmaceuticals manufacturer. Proceeds will be used for product research, aquaculture and KLH production development, capital expenditures and working capital. The financing represented continued support from Stellar's major shareholders, validation from industry investment and fiscal strength for the company to execute on its strategic plans.

Strategic program expansion; clostridium difficile active immunotherapy platform

In July, 2013, Stellar acquired the exclusive, worldwide licence to patented technology for the development of human immunotherapies against clostridium difficile infection (C. diff) from the University of Guelph in Canada. The licence broadens Stellar's business opportunities by adding a strong platform for the company's own proprietary active immunotherapy program. In October, 2013, the company announced presentation of positive results from a preclinical study related to the C. diff development program.

Environmental achievements and intellectual property

In 2013, Stellar announced several milestones further strengthening the company's competitive position and barriers to entry around its KLH business. Among these achievements was the industry-first capability to support the complete life cycle of the giant keyhole limpet (megathura crenulata), the scarce marine mollusk that is the only source for KLH protein. Stellar also announced new patents issued (in U.S. and China) related to its C. diff immunotherapy technology, as well as two U.S. patent applications for new KLH innovations developed at Stellar.

Stellar's strategic objectives for 2014 are:

  • Expand the Stellar KLH technology portfolio through continuing research and development and selective acquisition, while maintaining a strong balance sheet with careful resource management;
  • Seize opportunities for commercial growth that build on the company's strengths and core competencies in KLH development and immunotherapy;
  • Identify strategic pathways that leverage the company's Stellar KLH products and expertise into immunotherapy solutions;
  • Prepare for transition to major U.S. stock exchange.

Frank Oakes, Stellar's president and chief executive officer, said: "We are entering 2014 with unmatched competency in sustainable KLH manufacturing and focused on leveraging this position into new opportunities with key stakeholders and commercial partners in the biopharma industry. We have built high barriers around Stellar's technology platform, and we are now aggressively expanding with our own immunotherapy development program, further broadening our business potential. This combination of robust platform together with multiple avenues for strategic growth, positions Stellar to capture significant market interest in the future."

To view the company's fiscal 2013 consolidated financial statements, related notes, and management discussion and analysis as well as all of Stellar Biotechnologies' past reports and filings please visit the Canadian securities administrators' website. To view the company's fiscal 2013 annual report under Form 20-F, please visit the U.S. SEC website.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.